CytoMed Therapeutics Ltd GDTC
$1.03 $0.13 (14.57%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
GDTC Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, CytoMed Therapeutics Ltd is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
CytoMed Therapeutics Ltd. Stock Analysis GDTC
United States Health Care Nano Cap CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. The company employs 42 full-time employees The company went IPO on 2023-04-14. The company is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The firm also has the allogeneic gamma delta T cell technology, namely TCB-002.
CytoMed Therapeutics Ltd (GDTC) Chart
Financial Metrics & Statements of CytoMed Therapeutics Ltd (GDTC)
FAQ's for CytoMed Therapeutics Ltd (GDTC)
- As of August 2026, CytoMed Therapeutics Ltd GDTC is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes CytoMed Therapeutics Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in CytoMed Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of CytoMed Therapeutics Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of CytoMed Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of CytoMed Therapeutics Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for CytoMed Therapeutics Ltd (GDTC)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
